论文部分内容阅读
目的:探究围绝经期功能失调性子宫出血患者通过米非司酮治疗后取得的临床成效。方法:选取我院2015年1月-2016年6月入院的围绝经期功能失调性子宫出血患者80例,随机分为观察组和对照组各40人。观察组治疗方法为米非司酮治疗,对照组为其他类型性激素治疗。针对治疗前后性激素变化、不良反应情况,对两组进行对比。结果:在性激素水平方面,观察组治疗后优于对照组(P<0.05);观察组不良反应发生率(7.5%)显著低于对照组(25%),(P<0.05)。结论:围绝经期功能失调性子宫出血患者通过米非司酮治疗后取得的临床成效显著,在改善性激素水平的同时,使不良反应发生率明显降低,应大力推广应用。
Objective: To investigate the clinical efficacy of mifepristone in patients with dysfunctional uterine bleeding during perimenopausal period. Methods: Eighty patients with peri-menopausal dysfunctional uterine bleeding admitted to our hospital from January 2015 to June 2016 were randomly divided into observation group (40 cases) and control group (40 cases). Observation group treatment for mifepristone treatment, the control group for other types of sex hormones. Before and after treatment for sex hormone changes, adverse reactions, the two groups were compared. Results: The level of sex hormones in the observation group was better than that in the control group (P <0.05). The incidence of adverse reactions in the observation group (7.5%) was significantly lower than that in the control group (25%) (P <0.05). Conclusion: The clinical efficacy of mifepristone in patients with dysfunctional uterine bleeding during peri-menopausal period is significant. While improving sex hormone levels, the incidence of adverse reactions is significantly reduced, and should be promoted and applied.